Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
118
Views
0
CrossRef citations to date
0
Altmetric
Articles

Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis

Madeleine B. Hopsona Irving Medical Center, Columbia University, New York, NY, USA
,
Divaya Bhutanib Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
,
Shawn Sarkariab Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
,
Mathew S. Maurera Irving Medical Center, Columbia University, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-5400-5008
ORCID Icon,
Jan M. Griffina Irving Medical Center, Columbia University, New York, NY, USA
,
Markus Maparab Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
,
Suzanne Lentzschb Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-1708-7344
ORCID Icon &
Rajshekhar Chakrabortyb Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USACorrespondence[email protected]
 show all
Pages 2109-2113 | Received 05 Dec 2021, Accepted 26 Mar 2022, Published online: 23 Apr 2022

References

  • Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–157.
  • Szczygiel JA, Michalek P, Drozd-Sokolowska J, et al. Comparison of lambda and kappa light-chain cardiac amyloidosis in Polish patients diagnosed in cardiology department. Eur Heart J. 2020;41(Supplement_2):137.
  • Sidiqi MH, Aljama MA, Muchtar E, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv. 2018;2(7):769–776.
  • Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020–1026.
  • Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140(2):85–93.
  • Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Hematol Am Soc Hematol Educ Program. 2020;2020(1):363–371.
  • Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
  • Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
  • Schieferdecker A, Hörber S, Ums M, et al. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. Blood Cancer J. 2020;10(1):2.
  • Muchtar E, Gertz MA, Kyle RA, et al. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc. 2019;94(3):472–483.
  • Russo P, Palladini G, Foli A, et al. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid. 2011;18(sup1):92–93.
  • Stancu S, Calin C, Coriu D, et al. Sp115renal survival prognostic factors in patients with light chain amyloidosis. Nephrol Dial Transplant. 2019;34(Supplement_1):115.
  • Czyżewska E, Wiśniewska A, Waszczuk-Gajda A, et al. The role of light kappa and lambda chains in heart function assessment in patients with AL amyloidosis. J Clin Med. 2021;10(6):1274.
  • Xu L, Su Y. Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications. Exp Hematol Oncol. 2021;10(1):43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.